Dexcom Inc Stock Analysis
DXCM Stock | USD 134.30 0.44 0.33% |
DexCom Inc is fairly valued with Real Value of 130.74 and Target Price of 137.0. The main objective of DexCom stock analysis is to determine its intrinsic value, which is an estimate of what DexCom Inc is worth, separate from its market price. There are two main types of DexCom's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect DexCom's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of DexCom's stock to identify patterns and trends that may indicate its future price movements.
The DexCom stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. DexCom is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. DexCom Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and DexCom's ongoing operational relationships across important fundamental and technical indicators.
DexCom |
DexCom Stock Analysis Notes
About 100.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.53. DexCom Inc had not issued any dividends in recent years. The entity had 4:1 split on the 13th of June 2022. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people. To learn more about DexCom Inc call Kevin Sayer at 858 200 0200 or check out https://www.dexcom.com.DexCom Inc Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. DexCom's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding DexCom Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
DexCom Inc is unlikely to experience financial distress in the next 2 years | |
Over 100.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from benzinga.com: 1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today |
DexCom Inc Upcoming and Recent Events
Earnings reports are used by DexCom to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DexCom previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
8th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
8th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
DexCom Largest EPS Surprises
Earnings surprises can significantly impact DexCom's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-04-29 | 2021-03-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2019-07-31 | 2019-06-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.04 | 0.01 | 20 |
DexCom Thematic Classifications
In addition to having DexCom stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Medical EquipmentUSA Equities from Medical Equipment industry as classified by Fama & French |
DexCom Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DexCom is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DexCom Inc backward and forwards among themselves. DexCom's institutional investor refers to the entity that pools money to purchase DexCom's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Jpmorgan Chase & Co | 2023-12-31 | 5.7 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 5.5 M | American Century Companies Inc | 2023-12-31 | 5.3 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 5.1 M | Goldman Sachs Group Inc | 2023-12-31 | 4.9 M | Bank Of America Corp | 2023-12-31 | 4.7 M | Blair William & Co | 2023-12-31 | 4.5 M | Ubs Asset Mgmt Americas Inc | 2023-12-31 | 4.4 M | Norges Bank | 2023-12-31 | 4.4 M | Vanguard Group Inc | 2023-12-31 | 44.5 M | Blackrock Inc | 2023-12-31 | 32.7 M |
DexCom Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 52.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DexCom's market, we take the total number of its shares issued and multiply it by DexCom's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.DexCom Profitablity
DexCom's profitability indicators refer to fundamental financial ratios that showcase DexCom's ability to generate income relative to its revenue or operating costs. If, let's say, DexCom is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, DexCom's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of DexCom's profitability requires more research than a typical breakdown of DexCom's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.21 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.21. Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.09 | 0.09 | |
Return On Capital Employed | 0.13 | 0.13 | |
Return On Assets | 0.09 | 0.09 | |
Return On Equity | 0.26 | 0.27 |
Management Efficiency
DexCom Inc has return on total asset (ROA) of 0.0641 % which means that it generated a profit of $0.0641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2578 %, meaning that it created $0.2578 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.13. At this time, DexCom's Intangible Assets are very stable compared to the past year. As of the 18th of April 2024, Return On Tangible Assets is likely to grow to 0.09, while Debt To Assets are likely to drop 0.41.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.36 | 5.63 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | 4.95 | 5.19 | |
Enterprise Value Over EBITDA | 54.46 | 57.19 | |
Price Book Value Ratio | 23.16 | 24.31 | |
Enterprise Value Multiple | 54.46 | 57.19 | |
Price Fair Value | 23.16 | 24.31 | |
Enterprise Value | 220.9 M | 231.9 M |
The analysis of DexCom's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze DexCom's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of DexCom Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.207 |
Technical Drivers
As of the 18th of April 2024, DexCom shows the Downside Deviation of 1.72, mean deviation of 1.49, and Coefficient Of Variation of 1744.52. DexCom Inc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for DexCom Inc, which can be compared to its peers. Please confirm DexCom Inc jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if DexCom Inc is priced favorably, providing market reflects its regular price of 134.3 per share. Given that DexCom has jensen alpha of 0.0698, we urge you to verify DexCom Inc's prevailing market performance to make sure the company can sustain itself at a future point.DexCom Inc Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. DexCom middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for DexCom Inc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
DexCom Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DexCom insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Matthew Dolan over a month ago Disposition of 1003 shares by Matthew Dolan of DexCom at 131.3912 subject to Rule 16b-3 | ||
Yang Richard over six months ago DexCom exotic insider transaction detected | ||
Jorge Valdes over a year ago Exercise or conversion by Jorge Valdes of 10000 shares of DexCom subject to Rule 16b-3 |
DexCom Predictive Daily Indicators
DexCom intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of DexCom stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 37500.27 | |||
Daily Balance Of Power | 0.1826 | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 134.79 | |||
Day Typical Price | 134.62 | |||
Price Action Indicator | (0.27) | |||
Period Momentum Indicator | 0.44 | |||
Relative Strength Index | 65.34 |
DexCom Corporate Filings
F4 | 16th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 10th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 29th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 26th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 19th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 11th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 21st of February 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
DexCom Forecast Models
DexCom's time-series forecasting models are one of many DexCom's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary DexCom's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About DexCom Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how DexCom prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DexCom shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as DexCom. By using and applying DexCom Stock analysis, traders can create a robust methodology for identifying DexCom entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.20 | 0.21 | |
Operating Profit Margin | 0.17 | 0.17 | |
Net Profit Margin | 0.15 | 0.16 | |
Gross Profit Margin | 0.63 | 0.66 |
Current DexCom Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. DexCom analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. DexCom analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
137.0 | Strong Buy | 24 | Odds |
Most DexCom analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand DexCom stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of DexCom Inc, talking to its executives and customers, or listening to DexCom conference calls.
DexCom Stock Analysis Indicators
DexCom Inc stock analysis indicators help investors evaluate how DexCom stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading DexCom shares will generate the highest return on investment. By understating and applying DexCom stock analysis, traders can identify DexCom position entry and exit signals to maximize returns.
Begin Period Cash Flow | 643.3 M | |
Long Term Debt | 2.4 B | |
Common Stock Shares Outstanding | 425.5 M | |
Total Stockholder Equity | 2.1 B | |
Tax Provision | 168.9 M | |
Quarterly Earnings Growth Y O Y | 1.81 | |
Property Plant And Equipment Net | 1.2 B | |
Cash And Short Term Investments | 2.7 B | |
Cash | 566.3 M | |
Accounts Payable | 276.4 M | |
Net Debt | 2 B | |
50 Day M A | 128.5538 | |
Total Current Liabilities | 1.6 B | |
Other Operating Expenses | 3 B | |
Non Current Assets Total | 1.8 B | |
Forward Price Earnings | 77.5194 | |
Non Currrent Assets Other | 36.5 M | |
Stock Based Compensation | 150.8 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.31 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.